Skip to content
CancerIndex

Publication

Prognostic Significance of Tumor-Cell VISTA Expression on Survival Outcomes in Nivolumab-Treated Pleural Mesothelioma: The HOT1901 Retrospective Multi-Institutional Study.

Hiroshi Yokouchi, Hiroshi Nishihara, Yoshiyuki Kenmotsu, Kosuke Tsuji, Takayuki Kishikawa, Hajime Kikuchi, Eisaku Miyauchi, Yutaro Nagano, Kenya Kanazawa, Jun Sugisaka, Takayuki Ohkuri, Satoshi Oizumi

ImmunoTargets and therapyJan 1, 2026PMID 42639079doi:10.2147/ITT.S585001 PMC13500881Journal ArticlepubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-PUBMED-20260908-000002
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

BACKGROUND: Nivolumab is used as a second-line treatment for pleural mesothelioma (PM); however, predictive or prognostic biomarkers remain unclear. We aimed to identify factors associated with survival in nivolumab-treated PM patients. METHODS: This retrospective, multi-institutional cohort study…

Read on PubMed

Linked entities

Linked entities (1)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Candidate 1

Curated evidence

Evidence citing this paper (0)

Data not yet available

No curated evidence item cites this publication.